← boothcheck

Is DOCS overvalued?

boothcheck doesn't label DOCS overvalued or undervalued and publishes no house fair value, target price, or buy/sell rating. Individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. In the published model solve dated 2026-10-02T07:22:51.515Z, anchored at $28.50, DOCS is priced for the modeled path sustained for about 9.0 years. The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price. The report narrative was composed 2026-08-07. The more the price assumes beyond what Doximity, Inc. has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.

Derived from Doximity, Inc.'s SEC EDGAR filings via a reverse-DCF inversion. Last analyzed August 7, 2026.

Implied growth—
For about9.0 yrs
Held margin (input)—
Margin today—
Price vs asset value2.84x
Price vs earnings power2.86x
Price vs peer multiples0.93x
Price vs forward growth0.79x
Read the full DOCS report →
Get boothcheck's read on what DOCS's price is betting on, in your inbox when it moves. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.